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Opinion Statement
Immunotherapy for type I allergies is well established and is regarded to be the most
efficient treatment option besides allergen avoidance. As of today, different forms of
allergen preparations are used in this regard, as well as different routes of application.
Virus-like particles (VLPs) represent a potent vaccine platform with proven immunogenic-
ity and clinical efficacy. The addition of toll-like receptor ligands and/or depot-forming
adjuvants further enhances activation of innate as well as adaptive immune responses.
CpG motifs represent intensively investigated and potent direct stimulators of
plasmacytoid dendritic cells and B cells, while T cell responses are enhanced indirectly
through increased antigen presentation and cytokine release. This article will focus on the
function of VLPs loaded with DNA rich in nonmethylated CG motifs (CpGs) and the clinical
experience gained in the treatment of allergic rhinitis, demonstrating clinical efficacy also
if administered without allergens. Several published studies have demonstrated a bene-
ficial impact on allergic symptoms by treatment with CpG-loaded VLPs. Subcutaneous
injection of VLPs loaded with CpGs was tested with or without the adjuvant alum in the
presence or absence of an allergen. The results encourage further investigation of VLPs
and CpG motifs in immunotherapy, either as a stand-alone product or as adjuvants for
allergen-specific immunotherapy.
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Introduction
Respiratory allergies today are some of the most preva-
lent chronic diseases [1]. According to the Allergic Rhi-
nitis and its Impact on Asthma (ARIA) Initiative, allergic
rhinitis is defined as immunoglobulin (Ig)-E-mediated
inflammation of the nasal mucosa with the respective
symptoms upon allergen exposure [2]. Apart from aller-
gen avoidance, allergy immunotherapy (AIT) represents
the only causative treatment option [3–6].
Allergen-specific immunotherapy over 3–5 years re-
quires numerous allergen applications either subcutane-
ously or sublingually [7, 8], leading to symptom amelio-
ration, reduced use of medication, and better quality of
life [3–6]. Importantly, allergen-specific immunotherapy
has long-term effects [9, 10] and is disease modifying, as
it can prevent the progression of rhinitis to asthma [11–
13]. Despite all of these medical advantages over symp-
tomatic pharmacotherapy, fewer than 5 % of allergy
patients choose to get treated with AIT [14–16]. This is
mainly because of two disadvantages of current AIT pro-
tocols. The first disadvantage is that the numerous injec-
tions and visits to amedical office over years are very time
consuming for the patient. The second disadvantage is
that allergen injection is often associated with adverse
reactions, which are typically harmless and not bother-
some injection site reactions in subcutaneous immuno-
therapy (SCIT) and oral or gastrointestinal symptoms in
sublingual immunotherapy (SLIT); these are experienced
by the majority of patients, but adverse events in rare
cases may also range from severe systemic allergic reac-
tions to anaphylaxis [17]. Various novel strategies have
been proposed to enhance the efficacy and shorten the
course of therapy in order to also enhance its safety. These
strategies include the use of recombinant native major
allergens, as well as modified hypoallergenic allergens
[18], use of allergen-derived peptides representing CD4
T cell epitopes [19, 20, 21••], intralymphatic immuno-
therapy [22••, 23–26], epicutaneous immunotherapy
[27–34, 35••, 36], and also the use of adjuvants more
potent than alum, such as monophosphoryl lipid A
(MPLA) [37•] or CpG [38••], or the use of allergens
displayed on virus-like particles (VLPs) [39•, 40, 41].
All of the above strategies are based on the dogma
that AIT requires the allergen. This dogma has been
challenged, however, by recent data [41, 42••]. Omit-
ting the allergen from the vaccine would strike two birds
with one stone. First, this would make immunotherapy
safer by avoiding allergic adverse events. Second, one
vaccine could be used for all allergies. The present review
will discuss the scientific rationale behind this strategy
and the available clinical data.
Therapy
Use of VLPs
VLPs spontaneously assemble upon expression of virus or bacteriophage capsid
proteins (Fig. 1). Some of these VLPs, such as RNA phage-derived VLPs, spon-
taneously package bacterial RNA upon expression. This RNA may be replaced
by DNA rich in nonmethylated CpGmotifs (CpGs) [43, 44]. VLPs have proven
to be safe and well tolerated and are today broadly used for prophylactic
vaccination against hepatitis B virus and human papilloma virus [45••, 46••].
Fig. 1. Loading of virus-like particles (VLPs) with CG motifs (CpGs). In a first step, VLPs are disassembled, the RNA is removed in a
second step, and the VLPs are finally reassembled in the presence of CpG G10. This results in VLPs loaded with CpGs.
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VLPs are also currently being evaluated in therapeutic vaccination against cancer
and other noncommunicable chronic diseases, as well as infections [47].
Because of their natural function as carriers of genetic information, virus or
bacteriophage capsid-derived VLPs can readily be filled with DNA or RNA. VLPs
stabilize and protect these molecules from enzymatic degradation by DNAses
and RNAses. Bacteriophage-derived VLPs filled with immunostimulatory CpGs
have been used to display tumor antigens and were found to efficiently induce
tumor antigen-specific cytotoxic CD8 and CD4 T cells in melanoma patients
[48–50]. Similar CpGs were successfully used as adjuvants in prophylactic
vaccination to enhance B cell responses [51]. Overall, VLP technology bears
great potential for delivery of CpG in cancer, autoimmune disease, and allergies
[44]. The present review will focus on clinical experience using bacteriophage
VLPs filled with CpGs for treatment of allergic respiratory disease.
Immune responses induced by VLPs
VLPs can be subcutaneously or intramuscularly injected. Their diameter of
approximately 30 nm facilitates entry into lymphatic vessels and direct drainage
into local lymph nodes [52–54]. Once in the lymph node, VLPs are taken up by
lymph node resident dendritic cells (DCs). Again, this uptake is enhanced by
the size and form of VLPs [55]. VLPs are excellent inducers of CD4 T cells via the
major histocompatibility complex (MHC) class II pathway, but also cross
presentation on the MHC class I pathway is highly efficient [56, 57].
DCs can be subdivided into two main populations. While myeloid DCs
(mDCs) produce mainly interleukin (IL)-12, plasmacytoid DCs (pDCs) pro-
duce mainly interferon (IFN)-α [58–60]. CpGs are important inducers of
cytokines in these cells. There is, however, an important difference between
mice and humans. In mice, both pDCs and mDCs express toll-like receptor
(TLR)-9, while in humans, only pDCs express TLR9. Hence, IL-12 is hardly
induced in humans and the dominant cytokine is usually IFN-α [60, 61]. This
has important implications for the type of CpG thatmay be used for therapy, as
outlined below.
Overall, the immune response against VLPs is characterized by immunolog-
ical properties similar to those seen with live viral vaccines, but, in contrast
to the latter, VLPs have the following advantages:
1. The complete lack of genetic information with regard to viral replication
enhances safety. In contrast to attenuated vaccines, no reversion to the
virulent form is possible.
2. As VLPs assemble spontaneously, they can be produced cheaply in
Escherichia coli or yeast, in accordance with Good Manufacturing Practice
(GMP) guidelines.
3. The size and form of VLPs enhance lymphatic drainage and uptake by
antigen-presenting cells in the local lymph nodes.
4. Immunostimulatory CpGs or RNA can be packaged into VLPs and are
stabilized and protected from enzymatic digestion inside the VLPs [44].
Many protein and other antigens can readily be displayed on the surface of
VLPs. These antigens can either be genetically fused to the VLP protein, or
they can be chemically linked to the surface of the VLP. Hence, VLPs may be
used as a display platform to render antigens of choice highly immunogenic.
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CpG motifs
The human immune system can be activated by pathogen-associatedmolecular
patterns (PAMPs), which are common to nearly all pathogens. These include
nonmethylated CG-rich DNA sequences, which are common in the bacterial
genome but not in the genome of vertebrates, where these motifs are usually
methylated. Numerous such CpGs have been characterized and can be synthe-
sized as oligodeoxynucleotides (ODNs), using either the naturally occurring
“phosphodiester” bonding or the more stable “phosphorothioate” bonding in
the backbone of the molecule, hence the designation “C–p–G”. CpGs bind to
TLR9, which activates (via the adaptor molecule MyD88) the nuclear factor
(NF)-κB pathway, which starts the inflammatory cascade [62].
Three different types of CpGs have been distinguished—namely, A-, B-, and
C-type CpGs. Type A CpGs contain their CGmotifs in a palindromic sequence,
surrounded by guanosines. The backbone of type A CpGs consists of phos-
phodiester bonds, which are readily digested by DNAses. In contrast, the
backbone of type B CpGs consists of phosphorothioate bonds, which are
DNAse resistant. Type C CpGs are characterized by phosphorothioate bonds, as
well as CG motifs in palindromes on a phosphodiester backbone. These three
different types of CpGs differ in their immunological activities. Type A CpGs
induce mainly IFN-α, whereas type B CpGs are potent activators of B cells but
barely induce IFN-α. In mice, type B CpGs are potent inducers of IL-12 in
mDCs. But, as mentioned above, as human mDCs do not express TLR9, the IL-
12 response to this type of CpG is inefficient in humans. In addition, pDCs
essentially fail to respond to type B CpGs, as they produce only low levels of IL-
12 and do not respond with the production of IFN-α to stimulation with this
type of CpG. Thus, human DCs respond very poorly to B-type CpGs. Finally,
type C CpGs have the characteristics of both A- and B-type CpGs.
TLR9
While, in mice, TLR9 is expressed in both pDCs andmDCs, in humans, TLR9 is
expressed only in pDCs. TLR9 is also expressed in B cells, mast cells, neutro-
phils, eosinophils, basophils, and keratinocytes [63]. TLR9 is intracellularly
located, i.e., within the endosomes, which are accessed by phagocytosed path-
ogens first. Stimulation of TLR9 polarizes the immune response towards the T-
helper (Th)-1 type and stimulates immunoglobulin class switching toward
IgG2a in mice [64, 65] and IgG in humans [66]. Th1 cells, as well as IFN-α
production, can suppress Th2 cells [67] and downregulate IgE production. TLR
stimulation also has direct effects on mast cells, basophils, and eosinophils
[68]. The physiological relevance of these interactions is, however, less clear.
Rationale for use of VLPs as vaccines
The human immune system has evolved to efficiently recognize highly
repetitive structures, because such structures are typically found on the
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surfaces of viruses and bacteria. To speed up the antibody response, such
repetitive arrays of epitopes can crosslink such large numbers of B cell
surface receptors that antibody production is induced even in the absence
of T cell help. Therefore, repetitive antigens, such as those found on the
surface of VLPs, are known as “Th-independent antigens” [69••]. In addi-
tion, antigen-presenting cells have evolved to efficiently take up particles of
viral size and VLP content is scanned by TLRs in the endosomes. The
innate humoral immune system has finally also evolved to recognize
repetitive structures, enhancing both B cell activation and uptake/activation
of antigen-presenting cells [44].
Clinical trials with CpGs in immunotherapy for allergic rhinitis
Allergen covalently coupled to CpGs
Creticos et al. performed a clinical trial using the major ragweed allergen
Amb a 1 conjugated to a type B CpG-ODN in 25 ragweed-allergic patients
[38••]. In this randomized, double-blind, placebo-controlled phase II
study, adult patients received a total of six injections at weekly time inter-
vals. The primary endpoint, which was vascular permeability as measured
by the serum albumin concentration in nasal lavage, was not significantly
ameliorated in this trial. However, clinical symptoms of allergic rhinitis
were ameliorated and quality-of-life scores improved already during the
first season after treatment. This improvement persisted also in the fol-
lowing pollen season, i.e., 2 years after vaccination. The treatment proved
safe and well tolerated, with no severe adverse events. The authors also
observed absence of the IgE boost usually observed after the ragweed
season in the treatment group. The highly encouraging phase II clinical data
could, however, not be reproduced in a larger phase III clinical trial [70].
This may have been due to the fact that the ragweed pollen counts were
particularly low in the relevant season and symptoms consequently were
very minor also on placebo. On the other hand, use of B-type CpGs, which
inefficiently stimulate human DCs, may have resulted in reduced clinical
efficacy (Table 1).
Allergen conjugated to VLPs filled with RNA
We have performed an open-label phase I clinical trial with a house
dust mite (HDM) Der p 1-derived peptide of 16 amino acids in length,
which was covalently coupled by a chemical linker to bacteriophage
Qβ-derived VLPs filled with E. coli-derived RNA ligand for TLR7 and 8.
The vaccine was administered three times at 4-week time intervals.
Twenty-four healthy volunteers participated in this study, and anti-
body titers were followed for 18 months [39•]. The vaccine was well
tolerated, and we observed only local reactions at the site of injection.
Already 4 weeks after the first injection, we observed a rapid Der p 1-
specific serum IgM and IgG response. Interestingly, the IgG subclasses
were mainly IgG1 und IgG3—thus those subclasses typically observed
after viral infection, rather than the IgG4 response typically observed
after conventional AIT. We observed no differences between the
76 Specific Immunotherapy (L Cox, Section Editor)
intramuscular and the subcutaneous routes of injection [39•] (Table
1). It would be interesting to repeat this study with VLPs loaded with
CpGs rather than RNA.
Allergen admixed to VLPs filled with CpGs
In an additional clinical trial, we investigated the safety and tolerability, as
well as the clinical efficacy, of type-A CpGs packed in Qβ-derived VLPs. The
CpG-loaded VLPs weremixed with HDM allergens and used as an adjuvant
in specific immunotherapy [71] (Table 1). In order to keep the formulation
simple, CpG-containing VLPs were simply mixed with a conventional
HDM extract. Twenty HDM-allergic patients were included in this open-
label, monocentric clinical trial. The first few injections were performed
with the HDM extract only, following the conventional cluster regimen.
This short uptitration phase was followed by a total of six weekly injections
of HDM extract mixed with VLPs containing CpGs. The clinical endpoints
of this trial were conjunctival provocation testing, as well as monitoring of
allergic rhinitis and asthma, quality-of-life questionnaires, skin prick tests
and antibody measurements. We found a good safety and tolerability
profile. Symptoms of allergic rhinitis and asthma were significantly re-
duced, and allergen-specific IgG was found to increase. Allergen-specific
IgE, after an initial rise, was subsequently also found to decrease [71]. We
repeated that clinical trial in a double-blind and placebo-controlled man-
ner. In this clinical trial, HDM extract mixed with CpG-containing VLPs was
compared with HDM extract alone or with CpG-containing VLPs alone, or
with another arm containing only placebo (Senti et al., unpublished). This
trial could essentially confirm the results of the open-label study. We were
surprised, however, to find that the clinical effects with VLPs filled with
Table 1. Clinical trials using virus-like particles (VLPs) and CG motifs (CpGs) [41]
Vaccine Treatment arms Patients and
disease
Study design Reference
Qβ VLP coupled to Der
p
1-derived peptide (Qβ-Der
p
1). Note that this VLP was
loaded with E.coli RNA
i.m. 50
μg Qβ-Der
p
1 (n=6),
s.c. 50
μg Qβ-Der
p
24 volunteers;
healthy
Randomized,
monocentric,
open-label
[39•]
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CpG alone were as good as those obtained when the HDM extract was
admixed. These puzzling results were the starting point of a clinical trial
program where the allergen was to be omitted from allergen-specific
immunotherapy.
In the following clinical trial, we therefore used the same Qβ-derived
VLPs filled with the same type A CpG, named G10. The study was a
randomized, double-blind, placebo-controlled phase IIb trial in 299
patients suffering from allergic rhinoconjunctivitis due to HDM allergy
[42••] (Table 1). Patients received 6-weekly injections either with
verum or placebo. The study duration per patient was 9 weeks. The
clinical endpoints were the symptom and medication scores and
quality-of-life scores, as well as conjunctival provocation testing. The
treatment proved to be safe and well tolerated. Symptom and medica-
tion scores improved significantly in the high-dose verum group,
confirming that treatment with VLPs filled with CpGs alone could
ameliorate allergic rhinitis, even without injection of allergen.
Possible mechanisms of immunotherapy without allergens
Animal models suggest that type-A CpG-induced Th1 responses and IFN-α
inhibit Th2 responses. Furthermore, symptom amelioration could also be due to
direct effects of CpGs onmast cells, which also express TLR9 [72–74]. CpGs have
also been found to change the enzymatic activity of indoleamine 2,3
dioxygenase (IDO), an enzyme known to play an important role in T cell
regulation [75•]. Following CpG-induced IFN-α production, the cytokine was
found to upregulate IDO in DCs, leading to T cell suppression [76]. This
mechanismmay explain some of the inflammation-inhibiting effects of CpGs in
allergic diseases.On an epidemiological level, the “hygiene hypothesis” supports
the notion that bacterial byproducts have inhibitory effects on the development
of allergies, at least early in life [77••]. It is well known that children born and
raised on farms have a significantly lower risk of respiratory allergies and asthma.
The same is true for children born into households with many children, as well
as households with pets, and for children visiting day care centers [78–80]. The
persistent protective effect of exposure to bacterial byproducts early in life may
be explained by epigenetic modifications [81] or by long-lived Th1 cells, creating
a cytokinemilieu disfavoring the development of Th2 cells. CpGs have also been
found to activate ICOS ligands on pDCs, which represents an important
costimulatory molecule for the induction of regulatory T cells [82].
Last ,but not least, it should not be forgotten that if clinical trials are being
performed in HDM allergy, the latter allergens are nearly ubiquitous and
present during the entire season. It can therefore not be excluded that the
natural exposure to allergen plays a role in the “allergen-free” treatment regi-
mens being discussed.
Thus, treating allergies with CpG-loaded VLPs remains an attractive option
and may allow desensitization of a large number of patients in an efficient
manner in the absence of risk of anaphylactic reactions. However, there are a
number of questions that still need to be resolved, including finding the
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optimal dose and the duration of the therapeutic effect. Further clinical trials are
therefore required to elucidate whether “allergen-free” immunotherapy is a
valuable long-term treatment option for allergies.
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